The Courier & Advertiser (Angus and Dundee)
Partnership will be prepared for rapid vaccination
Professor hails distribution arrangement as ‘major force in struggle against pandemics’
Oxford University has partnered with pharmaceutical giant Astrazenenca for the development, manufacture and large-scale distribution of the Covid-19 vaccine candidate being tested in the UK.
The agreement was announced yesterday, with the details set to be finalised in the coming weeks.
The move will allow for rapid vaccination around the world if the candidate proves to be effective, the university said.
Human trials of the vaccine developed by the university’s Jenner Institute began last week, with hundreds of people volunteering to be part of the study which received £20 million in government funding.
Professor Sir John Bell, Regius Professor of Medicine at Oxford University described the partnership with Astrazeneca as a “major force in the struggle against pandemics” for the foreseeable future.
Speaking on BBC Radio 4’s Today programme, Sir John said he hoped some results from a human trial of the vaccine would be available by the middle of June.
He told Today the challenge now is to be able to manufacture at scale once it is approved by the regulators.
Sir John added: “We also want to make sure the rest of the world will be ready to make this vaccine at scale so it gets to populations in developing countries, for example, where the need is very great.
“We really need a partner to do that and that partner has a big job in the UK because our manufacturing capacity in the UK for vaccines isn’t where it needs to be, and so we are going to work together with Astrazeneca to improve that considerably.”
Health Secretary Matt Hancock said it was “hugely welcome news”.
He tweeted: “The Oxford vaccine is one of the most advanced in the world. Bringing together the best British science and the best of British business will give us the best possible shot at a vaccine.
“The science is uncertain, and no vaccine may work, but this deal gives the UK the best chance we can of a breakthrough that could defeat this awful virus. I’m sending best wishes to all involved – for the sake of the nation and indeed the whole world.”
Astrazeneca chief executive Pascal Soriot said investment in the new vaccine is a risk worth taking for his company.
He told Today: “It is definitely a risk to launch into development of this vaccine, but now is the time to take those risks – this is a terrible crisis we’re facing, and we need solutions.”